Castle Biosciences（CSTL）株式概要
分子診断薬会社であるキャッスル・バイオサイエンシズ社は、皮膚がん、バレット食道（BE）、アトピー性皮膚炎（AD）、ぶどう膜黒色腫の診断と治療のための検査ソリューションを提供している。 詳細
CSTL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Castle Biosciences, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$23.72 |
| 52週高値 | US$44.28 |
| 52週安値 | US$14.59 |
| ベータ | 1.0 |
| 1ヶ月の変化 | 14.59% |
| 3ヶ月変化 | -2.67% |
| 1年変化 | 21.64% |
| 3年間の変化 | 43.76% |
| 5年間の変化 | -63.40% |
| IPOからの変化 | 10.84% |
最新ニュース
ナラティブ更新 • Jul 09
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Analysts have raised the fair value estimate for Castle Biosciences stock by $5 to $35, citing Street research that highlights quality revenue growth potential, solid gross margins, and a path toward sustainable profitability as key supports for higher price targets. Analyst Commentary Recent Street research on Castle Biosciences reflects a mix of optimism about the company’s revenue outlook and profitability path, alongside more cautious adjustments to price targets that highlight execution and valuation risks.
ナラティブ更新 • Jun 25
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Analysts have updated their price outlook on Castle Biosciences to reflect a $44.0 target, with the shift framed by recent Street research that highlights both reduced targets from some firms in the $35 to $40 range and continued emphasis on revenue growth potential, profit prospects and a solid balance sheet. Analyst Commentary Recent Street research on Castle Biosciences presents a mix of optimism around growth and profitability alongside more cautious revisions to price targets, giving you a fuller picture of how expectations are being reset.Recent updates
ナラティブ更新 • Jul 09
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Analysts have raised the fair value estimate for Castle Biosciences stock by $5 to $35, citing Street research that highlights quality revenue growth potential, solid gross margins, and a path toward sustainable profitability as key supports for higher price targets. Analyst Commentary Recent Street research on Castle Biosciences reflects a mix of optimism about the company’s revenue outlook and profitability path, alongside more cautious adjustments to price targets that highlight execution and valuation risks.ナラティブ更新 • Jun 25
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Analysts have updated their price outlook on Castle Biosciences to reflect a $44.0 target, with the shift framed by recent Street research that highlights both reduced targets from some firms in the $35 to $40 range and continued emphasis on revenue growth potential, profit prospects and a solid balance sheet. Analyst Commentary Recent Street research on Castle Biosciences presents a mix of optimism around growth and profitability alongside more cautious revisions to price targets, giving you a fuller picture of how expectations are being reset.ナラティブ更新 • Jun 08
CSTL: Test Volume Execution And 2026 Guidance Will Underpin Upside Potential
Analysts have trimmed the price target on Castle Biosciences to $44.00 from $45.88, reflecting recent target reductions from multiple firms, even as they point to what they describe as solid test volume trends and ongoing upside potential in the stock. Analyst Commentary Recent Street commentary on Castle Biosciences points to a mixed setup, with target cuts clustered in the mid US$30s to low US$40s range and a focus on how execution in core tests might support that valuation.ナラティブ更新 • May 24
CSTL: 2026 Clinical Data And Guidance Will Support Upside Potential
Narrative Update: Castle Biosciences The updated analyst price target for Castle Biosciences shifts from $47.25 to $45.88 as analysts factor in the recent cuts in Street targets, along with views that solid Q1 volume growth in TissueCypher and DecisionDx-Melanoma still supports potential upside over time. Analyst Commentary Recent Street research on Castle Biosciences highlights a mix of optimism around execution and caution reflected in lower price targets.ナラティブ更新 • Apr 22
CSTL: 2026 Clinical Data And Guidance Will Support Higher Confidence
Analysts have trimmed their modeled fair value for Castle Biosciences to $47.25 from $48.50 as they recalibrate long term revenue growth, profit margin, and future P/E assumptions following a mix of recent price target increases and a reduction from different research firms. Analyst Commentary Bullish Takeaways Bullish analysts who raised their price targets highlight room for upside in their models, which typically reflects confidence in the company’s ability to execute on its current pipeline and commercial plans.ナラティブ更新 • Apr 04
CSTL: Preliminary 2025 Update Will Support Higher Confidence In 2026 Revenue
Analysts have lifted their price targets on Castle Biosciences by up to $17, reflecting updated models that now reference 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent price target changes cluster around updated 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure.Seeking Alpha • Mar 30
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Summary Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with high clinical utility, workflow integration, and payer support, targeting a large and growing melanoma market. I assign CSTL a conviction rating of 3/5, initiating a pilot position near technical support, with plans to build exposure as the market digests 2026 earnings and product adoption. Read the full article on Seeking Alphaナラティブ更新 • Mar 20
CSTL: Preliminary 2025 Revenue Signals Stronger Confidence In 2026 Outlook
Analysts have lifted their price targets on Castle Biosciences by amounts ranging up to $17, pointing to updated revenue estimates through 2026 and recent preliminary 2025 revenue disclosures as key drivers of their revised outlooks. Analyst Commentary Recent research notes focus on how preliminary 2025 revenue disclosures and updated 2026 revenue estimates feed into Castle Biosciences' valuation, with several firms adjusting their price targets to reflect these updated assumptions.ナラティブ更新 • Mar 06
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have modestly adjusted their fair value estimate for Castle Biosciences to $48.50, citing updated revenue growth and profit margin assumptions, as well as a slightly lower future P/E multiple, as reflected in recent price target increases from several firms. Analyst Commentary Recent research updates on Castle Biosciences have centered on revised revenue assumptions for 2025 and beyond, along with higher price targets that feed into the updated fair value estimate of $48.50.ナラティブ更新 • Feb 20
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have raised their average price target on Castle Biosciences by $14, citing updated models that now rely more on 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent research updates on Castle Biosciences focus heavily on how preliminary 2025 revenue information feeds into 2026 models, which in turn support higher price targets.ナラティブ更新 • Feb 05
CSTL: Preliminary 2025 Revenue Signals Will Support Extended 2026 Upside Potential
Narrative Update The updated analyst price target for Castle Biosciences moves from $46.00 to about $48.57. Analysts point to refreshed assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change.ナラティブ更新 • Jan 21
CSTL: Extended 2026 Revenue View And Test Adoption Will Support Upside
Narrative Update: Castle Biosciences Analysts have lifted their fair value estimate for Castle Biosciences from US$42.50 to US$46.00, citing updated modeling that now anchors price targets on 2026 revenue expectations following preliminary 2025 revenue disclosures. Analyst Commentary Recent Street commentary around Castle Biosciences is centering on how the preliminary 2025 revenue update reshapes expectations and valuation anchors out to 2026.ナラティブ更新 • Jan 06
CSTL: Dermatology Test Adoption And New Launches Will Support Balanced Outlook
Analysts have lifted their price target on Castle Biosciences from US$38.75 to US$42.50, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News New data from a prospective multicenter study comparing NGS-based mutation analysis with the combination of DecisionDx-UM and PRAME for uveal melanoma outcomes was published in Nature Communications, with DecisionDx-UM described as widely adopted in the U.S. standard of care and included in AJCC and NCCN guidelines (Key Developments).ナラティブ更新 • Dec 13
CSTL: Broader Dermatology Test Adoption Will Support Balanced Long-Term Outlook
Analysts have raised their price target on Castle Biosciences to approximately 38.75 dollars from about 35.63 dollars, citing stronger expectations for revenue growth and slightly improved profit margins, despite a modestly higher discount rate and lower projected future P E multiple. What's in the News An independent expert consensus panel endorsed Castle Biosciences DecisionDx-Melanoma test as providing robust, clinically validated prognostic information that improves melanoma risk stratification and supports more precise treatment decisions (expert consensus paper).分析記事 • Nov 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up
Despite an already strong run, Castle Biosciences, Inc. ( NASDAQ:CSTL ) shares have been powering on, with a gain of...分析記事 • Aug 24
What Castle Biosciences, Inc.'s (NASDAQ:CSTL) 30% Share Price Gain Is Not Telling You
The Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has done very well over the last month, posting an excellent...分析記事 • Jun 28
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 23
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
Unfortunately for some shareholders, the Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has dived 28% in the last...分析記事 • Apr 16
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
While Castle Biosciences, Inc. ( NASDAQ:CSTL ) might not have the largest market cap around , it saw a double-digit...Seeking Alpha • Apr 14
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Summary Castle Biosciences offers diverse diagnostic tests, with DecisionDx-Melanoma being a key revenue driver, but faces potential Medicare reimbursement loss for DecisionDx-SCC in 2025. The company is expanding its portfolio with TissueCypher and IDgenetix, showing strong growth, though IDgenetix faces uncertain long-term performance. Castle is well capitalized with $293 million in cash, providing a strong runway, but continues to burn cash, mainly on general and admin expenses. Trading near 52-week lows, CSTL stock presents a good entry point, but investors should watch for clarity on the SCC non-coverage issue. Read the full article on Seeking Alpha分析記事 • Feb 25
Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
新しいナラティブ • Feb 13
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.分析記事 • Dec 12
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Key Insights The projected fair value for Castle Biosciences is US$66.66 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Aug 16
Castle Biosciences: Inflection Into Profitability
Summary Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. Castle Biosciences faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field. Read the full article on Seeking Alpha分析記事 • Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Celebrations may be in order for Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders, with the analysts delivering a...分析記事 • Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders of Castle Biosciences, Inc. ( NASDAQ:CSTL ) will be pleased this week, given that the stock price is up...分析記事 • Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders are no doubt pleased to see that the share price has bounced 28...分析記事 • Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...株主還元
| CSTL | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -2.0% | 0.9% | 0.1% |
| 1Y | 21.6% | 31.9% | 20.3% |
業界別リターン: CSTL過去 1 年間で31.9 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: CSTL過去 1 年間で20.3 % の収益を上げたUS市場を上回りました。
価格変動
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 9.4% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CSTL 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CSTLの 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2007 | 942 | Derek Maetzold | castlebiosciences.com |
分子診断薬のキャッスル・バイオサイエンシズ社は、皮膚がん、バレット食道（BE）、アトピー性皮膚炎（AD）、ぶどう膜黒色腫の診断と治療のための検査ソリューションを提供している。同社は、浸潤性皮膚黒色腫患者のセンチネルリンパ節陽性の可能性と転移のリスクを予測するリスク層別化遺伝子発現プロファイル（GEP）検査であるDecisionDx-Melanoma、非異形成、不定形異形成、低悪性度異形成のBE患者における高悪性度異形成および／または食道癌の将来の発生を予測するリスク層別化スペイタロミクス検査であるTissueCypherを提供している；AdvanceAD-Txは、中等度から重度のAD患者（12歳以上）に対する全身治療選択の指針となる非侵襲的GEP検査であり、DecisionDx-SCCは、皮膚扁平上皮がんのGEP検査であり、MyPath Melanomaは、診断が困難なメラノサイト病変を有する患者に使用する診断用GEP検査である。また、ブドウ膜黒色腫患者の転移リスクを予測するリスク層別化GEP検査であるDecisionDx-UMも提供している。同社は皮膚科と消化器科の市場に製品を提供している。同社は2007年に法人化され、テキサス州フレンズウッドに本社を置いている。
Castle Biosciences, Inc. 基礎のまとめ
| CSTL 基礎統計学 | |
|---|---|
| 時価総額 | US$719.43m |
| 収益（TTM） | -US$12.83m |
| 売上高(TTM) | US$339.92m |
2.1x
P/Sレシオ-56.1x
PER（株価収益率CSTL は割高か？
公正価値と評価分析を参照収益と収入
| CSTL 損益計算書（TTM） | |
|---|---|
| 収益 | US$339.92m |
| 売上原価 | US$75.18m |
| 売上総利益 | US$264.74m |
| その他の費用 | US$277.57m |
| 収益 | -US$12.83m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 30, 2026
| 一株当たり利益（EPS） | -0.42 |
| グロス・マージン | 77.88% |
| 純利益率 | -3.78% |
| 有利子負債／自己資本比率 | 2.2% |
CSTL の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/13 16:33 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Castle Biosciences, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |